Renovorx Stock Performance
| RNXT Stock | USD 0.97 0.02 2.02% |
The company holds a Beta of 1.29, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, RenovoRx will likely underperform. At this point, RenovoRx has a negative expected return of -0.3%. Please make sure to check RenovoRx's potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if RenovoRx performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days RenovoRx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
1 | RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform | 12/30/2024 |
2 | Disposition of 34390 shares by Kocak Ron of RenovoRx at 2.19 subject to Rule 16b-3 | 12/31/2024 |
3 | Acquisition by Shaun Bagai of 40983 shares of RenovoRx at 1.22 subject to Rule 16b-3 | 01/15/2025 |
4 | Acquisition by Marton Laurence of 25099 shares of RenovoRx at 1.33 subject to Rule 16b-3 | 01/17/2025 |
5 | RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025 | 01/27/2025 |
6 | Acquisition by Agah Ramtin of 65000 shares of RenovoRx at 3.29 subject to Rule 16b-3 | 02/06/2025 |
7 | RenovoRx Announces Pricing of 12.1 Million Underwritten Public Offering of Common Stock | 02/07/2025 |
8 | RenovoRx Announces Closing of 12.1 Million Underwritten Public Offering of Common Stock | 02/11/2025 |
9 | RenovoRx Highlights Promising Pre-Clinical Data Abstract TAMP Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery | 02/13/2025 |
| Begin Period Cash Flow | 4.4 M |
RenovoRx |
RenovoRx Relative Risk vs. Return Landscape
If you would invest 127.00 in RenovoRx on November 28, 2024 and sell it today you would lose (30.00) from holding RenovoRx or give up 23.62% of portfolio value over 90 days. RenovoRx is currently does not generate positive expected returns and assumes 5.6061% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than RenovoRx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
RenovoRx Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for RenovoRx's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as RenovoRx, and traders can use it to determine the average amount a RenovoRx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0543
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RNXT |
Estimated Market Risk
| 5.61 actual daily | 50 50% of assets are less volatile |
Expected Return
| -0.3 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average RenovoRx is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of RenovoRx by adding RenovoRx to a well-diversified portfolio.
RenovoRx Fundamentals Growth
RenovoRx Stock prices reflect investors' perceptions of the future prospects and financial health of RenovoRx, and RenovoRx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RenovoRx Stock performance.
| Return On Equity | -2.59 | ||||
| Return On Asset | -0.93 | ||||
| Current Valuation | 24.93 M | ||||
| Shares Outstanding | 35.57 M | ||||
| Price To Book | 4.88 X | ||||
| EBITDA | (11.39 M) | ||||
| Net Income | (10.23 M) | ||||
| Cash And Equivalents | 10.77 M | ||||
| Cash Per Share | 1.19 X | ||||
| Total Debt | 4.47 M | ||||
| Current Ratio | 10.01 X | ||||
| Book Value Per Share | 0.29 X | ||||
| Cash Flow From Operations | (10.26 M) | ||||
| Earnings Per Share | (0.58) X | ||||
| Market Capitalization | 34.49 M | ||||
| Total Asset | 1.47 M | ||||
| Retained Earnings | (41.41 M) | ||||
| Working Capital | 291 K | ||||
About RenovoRx Performance
Assessing RenovoRx's fundamental ratios provides investors with valuable insights into RenovoRx's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the RenovoRx is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (8.03) | (7.63) | |
| Return On Capital Employed | (45.04) | (42.78) | |
| Return On Assets | (8.03) | (7.63) | |
| Return On Equity | 3.07 | 3.22 |
Things to note about RenovoRx performance evaluation
Checking the ongoing alerts about RenovoRx for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for RenovoRx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| RenovoRx generated a negative expected return over the last 90 days | |
| RenovoRx has high historical volatility and very poor performance | |
| RenovoRx has some characteristics of a very speculative penny stock | |
| RenovoRx has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (10.23 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| RenovoRx currently holds about 10.77 M in cash with (10.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from businesswire.com: RenovoRx Highlights Promising Pre-Clinical Data Abstract TAMP Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery |
- Analyzing RenovoRx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RenovoRx's stock is overvalued or undervalued compared to its peers.
- Examining RenovoRx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating RenovoRx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of RenovoRx's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of RenovoRx's stock. These opinions can provide insight into RenovoRx's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.